510(k) device
HAL for Medical Use(Lower Limb type)
Cyberdyne, Inc. · Powered Exoskeleton (PHL, Class II) · First FDA decision Dec 17, 2017, newest Oct 2, 2020Mobility impairmentSpinal cord injury and paralysis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
25
Naming "HAL"
MAUDE reports
0
Brand "HAL", since 2015
PubMed studies
2,833
Mentioning "HAL"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing HAL for Medical Use(Lower Limb type)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K201559 · Decided Oct 2, 2020 · 114 days after receipt
Device type: Powered Exoskeleton (PHL) · Physical Medicine & Rehabilitation
K171909 · Decided Dec 17, 2017 · 174 days after receipt
Device type: Powered Exoskeleton (PHL) · Physical Medicine & Rehabilitation
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Challenge Ingestion Food TestingNational determinationOn the books110.12Updated Apr 17, 2020
- Cardiointegram (CIG) as an Alternative to Stress Test or Thallium Stress TestNational determinationOn the books20.27Updated Apr 17, 2020
- Electroencephalographic Monitoring During Surgical Procedures Involving the Cerebral VasculatureNational determinationOn the books160.8Updated Jan 23, 2017
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)Local determinationIn effectL34061CGS Administrators, LLCUpdated Jul 27, 2026
- Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)Local determinationIn effectL34380Wellpoint FederalUpdated Jul 14, 2026
- Ophthalmic Biometry for Intraocular Lens Power CalculationLocal determinationIn effectL33621Wellpoint FederalUpdated Jul 14, 2026
- Ophthalmology: Posterior Segment Imaging (Extended Ophthalmoscopy and Fundus Photography)Local determinationIn effectL33567Wellpoint FederalUpdated Jul 14, 2026
- Ophthalmic Biometry for Intraocular Lens Power CalculationLocal determinationIn effectL34181CGS Administrators, LLCUpdated May 29, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "HAL", any status and sponsor, newest update first.
- Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light ResectionPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06525571 · 200 participants (planned) · Start Dec 20, 2024 · Primary completion Jan 4, 2027
Device: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system · For: Bladder Cancer
Sites: Washington D.C., District of Columbia; Baltimore, Maryland
- A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia ControlPivotal-lookingRecruiting
Jaeb Center for Health ResearchAcademic, hospital or other
NCT07095894 · 348 participants (planned) · Start Jul 1, 2026 · Primary completion Jul 1, 2029
Device: Spectacles with HAL · For: Myopia
Sites: Birmingham, Alabama; Tucson, Arizona; Fullerton, California · 18 sites in all
- Effectiveness and Tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)Pivotal-lookingCompleted
Bitop AGNot on our public-company list
NCT04203810 · 194 participants · Start Jan 14, 2020 · Primary completion Dec 4, 2020
Device: Ectoin® Mouth and Throat Spray Althaea Honey (ERS09); EMSER® Hals-und Rachenspray (throat spray) · For: Sore Throat; Acute Pharyngitis; Cough
Sites: Aachen, Germany; Arnsberg, Germany; Bad Schönborn, Germany · 12 sites in all
22 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "HAL", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PHL
57 reports: 7 malfunction, 50 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "HAL"[tiab]. The summary above synthesizes these.
- Disease-associated marked hyperalphalipoproteinemia.
Hirano KI, Nagasaka H, Kobayashi K, et al. · Mol Genet Metab Rep · 2014
- Hepatoid Adenocarcinoma of the Lung.
Li M, Fan Y, Lu H · Technol Cancer Res Treat · 2021Research Support, Non-U.S. Gov't
- Comparison of the performance of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) and highly aspherical lenslets (HAL) spectacles.
Lembo A, Schiavetti I, Serafino M, et al. · BMJ Paediatr Open · 2024Comparative Study
- Hyperactive learning for data-driven interatomic potentials.
van der Oord C, Sachs M, Kovács DP, et al. · NPJ Comput Mater · 2023
- The Peripheral Defocus Designed Spectacle Lenses Might Increase Astigmatism in Myopic Children.
Xu W, Li X, Zhang J, et al. · Transl Vis Sci Technol · 2025
- Myopia Control Efficacy of Spectacle Lenses With Aspherical Lenslets: Results of a 3-Year Follow-Up Study.
Li X, Huang Y, Yin Z, et al. · Am J Ophthalmol · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Sublethal effects of halofenozide on larval development and detoxification in Phaedon brassicae (Coleoptera: Chrysomelidae).
Ma L, Xu C, Peng Y, et al. · J Econ Entomol · 2023Research Support, Non-U.S. Gov't
- Prince Hal's conflict.
KRIS E · Psychoanal Q · 1948
- Characteristics of the most viewed Hybrid Assistive Limb-related videos on YouTube.
Nagasawa M, Nakamura S, Narimatsu H · Health Informatics J · 2024
- Hepatoid adenocarcinoma of the lung: A case report.
Mo YJ, Lin LN, Tao JL, et al. · World J Clin Cases · 2024Case Reports
- Gait improvement with wearable cyborg HAL trunk unit for parkinsonian patients: five case reports.
Uehara A, Kawamoto H, Imai H, et al. · Sci Rep · 2023Case Reports, Research Support, Non-U.S. Gov't
- Hypoxia-activated ligand HAL-1/13 is lupus autoantigen Ku80 and mediates lymphoid cell adhesion in vitro.
Lynch EM, Moreland RB, Ginis I, et al. · Am J Physiol Cell Physiol · 2001Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
Other devices of this type
Also filed under product code PHL.
- Indego(R)Parker-Hannifin Corporation · 510(k) 2018
- Atalante XWandercraft SAS · 510(k) 2025
- ReWalk P6.0Re Walk Robotics , Ltd. · 510(k) 2023
- EksoNREkso Bionics, Inc. · 510(k) 2022
- Ekso (version 1.1) and Ekso GT (version 1.2)Ekso Bionics, Inc. · 510(k) 2016
- Trexo TheoTrexo Robotics, Inc. · 510(k) 2026
- EveWandercraft SAS · 510(k) 2026
- ReWalk® 7 Personal Exoskeleton (50-20-0005)Rewalk Robotics Ltd. Dba Lifeward · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.